Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate plus alfentanil vs propofol plus remifentanil for gastroscopy sedation
ChiCTR2000040058Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, alfentanil, propofol and remifentanil in None (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Incidence of respiratory depression and Sedation success rate. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
remimazolamalfentanilpropofolremifentanil
Beyond the preview
Go deeper on ChiCTR2000040058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040058.